Yext, Inc. (YEXT) · Oct 14, 2026 · Other events
11M-share CEO option — 11.0M shares; $21.00-$88.08 performance targets at a $7.00 exercise price
Yext’s new CEO stock option ties 11 million shares to extreme price hurdles, but creates sizable potential dilution and requires shareholder approval.
Yext is repositioning itself as an enterprise agentic-marketing platform built around structured data, AI visibility, and search discovery, but its near-term operating picture remains transitional: six-month revenue fell 2% year over year, primarily because of customer attrition, even as ARR stood at $440.8 million in the latest quarter.
The filing creates a very large, highly performance-dependent CEO incentive. The Board granted CEO Michael Walrath an option for 11,000,000 shares, intended to be his sole new equity compensation for the next ten years. 〔0〕 The option does not vest with time; shares become earned only after Yext sustains demanding stock-price hurdles, beginning at $21 and reaching $88.08, versus a $7.00 exercise price. 〔1〕
That structure is more shareholder-aligned than a conventional time-based grant, but the scale is the buried issue. Yext had 98.98 million shares outstanding as of August 18, 2026, so the 11 million underlying shares equal roughly 11% of the current share count before considering the exercise proceeds. The upside is that virtually all of the award depends on a sustained, substantial increase from the $6.93 pre-grant closing price; the cost is potentially material dilution if the business eventually delivers that appreciation.
Approval and governance risk remain unresolved. The option was granted outside Yext’s existing equity plan, cannot be exercised without stockholder approval, and is forfeited if approval is not obtained within twelve months. 〔2〕 That makes the next key event a shareholder decision rather than an immediate change to outstanding shares.
Bottom line: This is a bold long-term bet on the CEO’s ability to turn Yext’s AI-search repositioning into major value creation, not a routine compensation grant. The performance hurdles are unusually demanding, but the potential 11% share-count impact makes shareholder approval and dilution the central trade-off.
Stockholder vote on option approval within 12 months
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!